GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how next-gen “small molecule” drugs ...

Although GLP-1 pills and injections work similarly for weight loss management for people with obesity, they have different administration schedules and costs.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist. The glucagon-like peptide-1 (GLP-1) class has transformed ...

Oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and obesity care. Amid the enthusiasm, however, a quieter and clinically important ...

Originally developed for Type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the weight-loss medication market. And in recent years, their popularity has soared due to ...

Orforglipron (LY3502970) is a small-molecule, non-peptide GLP-1RA designed for oral use. Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption ...

Please provide your email address to receive an email when new articles are posted on . Oral semaglutide 25 mg is a once-daily medication approved to reduce body weight for adults with overweight or ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk plans to launch the once-daily oral semaglutide in the US in early January ...